Page last updated: 2024-11-06

rutecarpine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Rutecarpine is a quinazoline alkaloid isolated from the medicinal plant _Ruta graveolens_. It has been shown to exhibit a wide range of pharmacological activities, including anti-inflammatory, anti-cancer, and anti-oxidant effects. It is of interest for its potential to modulate the activity of various enzymes and signaling pathways. Rutecarpine is also studied for its potential therapeutic applications in the treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The synthesis of rutecarpine has been achieved through various methods, including the use of enzymatic catalysis and organocatalysis. Researchers are interested in further understanding the mechanisms of action of rutecarpine and developing more efficient methods for its synthesis and delivery. '

rutacarpine: from Evodia rutaecarpa; an ingredient in zhuyu hewei zhitong capsules [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65752
CHEMBL ID85139
CHEBI ID8922
SCHEMBL ID288507
MeSH IDM0091938

Synonyms (93)

Synonym
chebi:8922 ,
CHEMBL85139 ,
MLS002153304
smr001230721
SMP2_000103
LOPAC0_001091
OPREA1_313284
rutacarpine
nsc258317
rutaecarpin
indolo[2',4]pyrido[2,1-b]quinazolin-5(7h)-one, 8,13-dihydro-
rhetine
nsc-258317
NCI60_002069
indolo(2',3':3,4)pyrido(2,1-b)quinazolin-5(7h)-one, 8,13-dihydro-
c18h13n3o
nsc 258317
EU-0101091
rutaecarpine, >98% (hplc)
lopac-r-3277
NCGC00015892-01
8,13-dihydroindolo(2',3':3,4)pyrido(2,1-b)quinazolin-5(7h)-one
UPCMLD-DP040:001
84-26-4
rutaecarpine
rutecarpine
C09238
UPCMLD-DP040
NCGC00094364-03
NCGC00094364-04
NCGC00094364-01
inchi=1/c18h13n3o/c22-18-13-6-2-4-8-15(13)20-17-16-12(9-10-21(17)18)11-5-1-3-7-14(11)19-16/h1-8,19h,9-10h
NCGC00015892-02
R 3277
NCGC00015892-05
cid_65752
bdbm50131046
8,13-dihydro-7h-indolo[2'',3'':3,4]pyrido[2,1-b]quinazolin-5-one
FT-0653229
HMS3263K04
AKOS005720935
8xzv289pry ,
unii-8xzv289pry
R0102
CCG-205168
HMS2233M24
NCGC00015892-06
NCGC00015892-04
NCGC00015892-03
STL146385
8,13-dihydroindolo[2',3':3,4]pyrido[2,1-b]quinazolin-5(7h)-one
NCGC00015892-07
LP01091
S2349
HMS3374B10
rutecarpine [mi]
SCHEMBL288507
BBL028393
tox21_501091
NCGC00261776-01
8,13-dihydro-indolo(2',3':3,4)pyrido(2,1-b)quinazolin-5(7h)-one
DTXSID00232884
MLS006011796
7,8-dihydroindolo[2',3':3,4]pyrido[2,1-b]quinazolin-5(13h)-one
AC-34838
Q-100850
ACVGWSKVRYFWRP-UHFFFAOYSA-N
8,13-dihydro-indolo[2',3':3,4]pyrido[2,1-b]quinazolin-5(7h)-one
mfcd00210551
3,13,21-triazapentacyclo[11.8.0.0^{2,10}.0^{4,9}.0^{15,20}]henicosa-1(21),2(10),4,6,8,15,17,19-octaen-14-one
indolo[2',3':3,4]pyrido[2,1-b]quinazolin-5(7h)-one, 8,13-dihydro-
CS-6160
HY-N0147
GS-3618
HMS3656C09
sr-01000076104
SR-01000076104-2
SR-01000076104-6
3,13,21-triazapentacyclo[11.8.0.0^{2,10}.0^{4,9}.0^{15,20}]henicosa-1(21),2(10),4(9),5,7,15(20),16,18-octaen-14-one
NCGC00015892-08
SW220226-1
BCP21309
rutaecarpine (rutecarpine)
rutaecarpine,(s)
Q15424771
SDCCGSBI-0051061.P002
NCGC00015892-13
HMS3884P13
H10091
A864154
3,13,21-triazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-1(21),2(10),4,6,8,15,17,19-octaen-14-one
EN300-302963
Z2768165384

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" EF is a toxic drug and causes hepatotoxicity in humans."( Toxicity of Evodiae fructus on rat liver mitochondria: the role of oxidative stress and mitochondrial permeability transition.
Cai, Q; Li, W; Shi, S; Wang, Q; Wei, J; Wei, R; Zhang, Y; Zhao, W, 2014
)
0.4

Pharmacokinetics

ExcerptReferenceRelevance
" It was applied to the pharmacokinetic study of rutaecarpine in rat after a 2 mg/kg intravenous administration."( High-performance liquid chromatographic determination of rutaecarpine in rat plasma: application to a pharmacokinetic study.
Chen, CF; Chou, CJ; Hsu, SY; Ko, HC; Li, SY; Tsai, TH, 1994
)
0.29
" To evaluate the pharmacokinetic interaction of theophylline with rutaecarpine, the effects of rutaecarpine on CYP1A2 activity and theophylline pharmacokinetics were investigated."( Alteration of the pharmacokinetics of theophylline by rutaecarpine, an alkaloid of the medicinal herb Evodia rutaecarpa, in rats.
Chen, RM; Chen, TL; Don, MJ; Tsai, TH; Ueng, YF, 2005
)
0.33
" Pharmacokinetic data were calculated by a non-compartmental model."( Effects of Evodia rutaecarpa and rutaecarpine on the pharmacokinetics of caffeine in rats.
Chang, CH; Lin, LC; Tsai, TH, 2005
)
0.33
" These results suggest that rutaecarpine might cause changes in the pharmacokinetic parameters of APAP in rats."( The effects of rutaecarpine on the pharmacokinetics of acetaminophen in rats.
Bista, SR; Jahng, Y; Jeong, H; Jeong, TC; Kang, MJ; Kim, DH; Lee, SK, 2007
)
0.34
"To establish a SPE-HPLC method for the determination and pharmacokinetic study of evodiamine and rutacarpine in rat plasma."( [Determination of evodiamine and rutaecarpine of compound Wuzhuyu cataplasm in plasma by SPE-HPLC: application to its pharmacokinetics].
Kang, C; Li, M; Liu, S; Tong, H; Wang, Y; Yin, W; Zhou, Z, 2009
)
0.35
"After transdermal administration to rats, the pharmacokinetic behavior of evodiamine and rutaecarpine belongs to the one-compartment model."( [Determination of evodiamine and rutaecarpine of compound Wuzhuyu cataplasm in plasma by SPE-HPLC: application to its pharmacokinetics].
Kang, C; Li, M; Liu, S; Tong, H; Wang, Y; Yin, W; Zhou, Z, 2009
)
0.35
" It is proved to be suitable for pharmacokinetic study of evodiamine and rutaecarpine."( [Determination of evodiamine and rutaecarpine of compound Wuzhuyu cataplasm in plasma by SPE-HPLC: application to its pharmacokinetics].
Kang, C; Li, M; Liu, S; Tong, H; Wang, Y; Yin, W; Zhou, Z, 2009
)
0.35
"5, 3 and 4h) after administration, the concentrations of Rut and Evo in rat whole blood were determined by HPLC, and main pharmacokinetic parameters were calculated."( Pharmacokinetic comparisons of rutaecarpine and evodiamine after oral administration of Wu-Chu-Yu extracts with different purities to rats.
Chen, F; Ding, J; He, L; Li, Y; Peng, J; Xu, S; Zhang, J, 2012
)
0.38
" Furthermore, the newly developed method is successfully used for the determination of evodiamine and rutecarpine in rabbit plasma for pharmacokinetic study."( Simultaneous determination of evodiamine and rutecarpine in rabbit plasma by LC-ESI-MS and its application to pharmacokinetics.
Cai, J; Li, W; Lin, C; Lin, G; Ma, J; Pan, J; Pan, X; Wang, X, 2011
)
0.84
"The method described in this report has high sensitivity and selectivity, and was suitable for pharmacokinetic studies of evodiamine and rutaecarpine."( [Studies on pharmacokinetics of evodiamine and rutaecarpine in rats plasma after oral administration extracts of euodiae fructus].
Bao, T; Dong, Y; Li, Y; Weng, X; Yang, Q; Zhang, Y; Zhu, X, 2011
)
0.37
"A simple and sensitive high-performance liquid chromatographic method was developed for the simultaneous determination and pharmacokinetic analysis of seven alkaloids dehydroevodiamine (DHED), 10-hydroxyrutaecarpine (HDR), evodiamine (EDM), rutaecarpine (RCP), 1-methyl-2-n-nonyl-4(1H)quinolone (MNQ), evocarpine (ECP), and dihydroevocarpine (DHE), and two flavonoids isorhamnetin-7-O-rutinoside (RIM) and diosmetin-7-O-β-d-glucopyranoside (GRD) in rat plasma after oral administration of Wuzhuyu decoction."( Simultaneous determination and pharmacokinetic analysis of seven alkaloids and two flavonoids from rat plasma by HPLC-DAD after oral administration of Wuzhuyu decoction.
Hu, CQ; Li, F; Yang, XW, 2012
)
0.38

Compound-Compound Interactions

ExcerptReferenceRelevance
" Rutaecarpine has been used in combination with other drugs in the treatment of disorders and found to produce herb-drug interactions."( Rutaecarpine effects on expression of hepatic phase-1, phase-2 metabolism and transporter genes as a basis of herb-drug interactions.
Jin, T; Liu, J; Lu, YF; Wu, Q; Zhang, D; Zhu, QN, 2013
)
0.39
"To evaluate the effect of 5-fluorouracil (5-FU) combined with rutaecarpine (RUT) on the antiproliferative, anti-migratory, and apoptosis-promoting ability of colorectal cancer (CRC) cells and explore the underlying mechanism."( 5-Fluorouracil Combined with Rutaecarpine Synergistically Suppresses the Growth of Colon Cancer Cells by Inhibiting STAT3.
Chan, S; Chen, J; Chen, W; Sun, R; Wang, M; Wang, X; Wang, Z; Yu, Z; Zhang, H; Zuo, X, 2023
)
0.91
"In this study, we found that 5-FU combined with RUT can inhibit the proliferative, migratory, and antiapoptotic abilities of CRC cells to a significantly greater extent than either RUT or 5-FU alone both in vivo and in vitro."( 5-Fluorouracil Combined with Rutaecarpine Synergistically Suppresses the Growth of Colon Cancer Cells by Inhibiting STAT3.
Chan, S; Chen, J; Chen, W; Sun, R; Wang, M; Wang, X; Wang, Z; Yu, Z; Zhang, H; Zuo, X, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
" Furthermore, the rutaecarpine-loaded microemulsion gave significantly higher AUC and Cmax than did suspension, suggesting that the oral bioavailability of rutaecarpine in this microemulsion system could be enhanced due to the enhanced solubility of rutaecarpine by microemulsion."( Short communication: in vivo evaluation of microemulsion system for oral and parenteral delivery of rutaecarpine to rats.
Bhamdari, K; Choi, HG; Jahng, Y; Kim, DH; Lee, MH; Park, BJ; Woo, JS; Yong, CS; Yoo, BK, 2007
)
0.34
"The bioavailability of Rut and Evo was increased along with the increasing of purity (16%-80%) in Wu-Chu-Yu extracts."( Pharmacokinetic comparisons of rutaecarpine and evodiamine after oral administration of Wu-Chu-Yu extracts with different purities to rats.
Chen, F; Ding, J; He, L; Li, Y; Peng, J; Xu, S; Zhang, J, 2012
)
0.38
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Dose-response relationships for evodiamine, rutaecarpine and capsaicin were obtained."( The positive inotropic and chronotropic effects of evodiamine and rutaecarpine, indoloquinazoline alkaloids isolated from the fruits of Evodia rutaecarpa, on the guinea-pig isolated right atria: possible involvement of vanilloid receptors.
Hoshikuma, K; Kamiya, T; Kobayashi, Y; Nakano, Y; Yokoo, Y, 2001
)
0.31
" Thus, the microemulsion system composed of castor oil, PEG 400, Tween 80, and water could be a stable dosage form for rutaecarpine."( Physicochemical characterization of rutaecarpine-loaded microemulsion system.
Choi, HG; Jahng, Y; Kim, JK; Kim, JO; Park, BJ; Park, YJ; Rhee, JD; Yong, CS; Yoo, BK, 2005
)
0.33
" Thus, our results indicated that the microemulsion system composed of castor oil, polyethylene glycol 400, Tween 80, and water could be a more effective oral and parenteral dosage form for rutaecarpine."( Short communication: in vivo evaluation of microemulsion system for oral and parenteral delivery of rutaecarpine to rats.
Bhamdari, K; Choi, HG; Jahng, Y; Kim, DH; Lee, MH; Park, BJ; Woo, JS; Yong, CS; Yoo, BK, 2007
)
0.34
" It was concluded that a change of the dosage from the crude drug to solid dispersion could improve significantly the efficiency of rutaecarpine absorption and increase its plasma concentration."( Solid dispersion of rutaecarpine improved its antihypertensive effect in spontaneously hypertensive rats.
Ding, JS; Gao, R; Li, D; Li, YJ; Peng, J; Ran, LL, 2008
)
0.35
" In comparison to capsaicin, coadministration of 1 and capsaicin increased the half-maximal effective concentration (EC50) of capsaicin-activated TRPV1 currents as shown by a right shift in the dose-response curve, whereas coadministration of 1 with protons failed to inhibit the proton-induced current."( Partial Activation and Inhibition of TRPV1 Channels by Evodiamine and Rutaecarpine, Two Major Components of the Fruits of Evodia rutaecarpa.
Dai, Y; Kogure, Y; Noguchi, K; Wang, S; Yamamoto, S; Zhang, W, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
beta-carbolinesAny pyridoindole containing a beta-carboline skeleton and their hydrogenated derivatives
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (80)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency6.30960.044717.8581100.0000AID485294
Chain A, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency28.18380.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency39.81075.623417.292931.6228AID2323
Chain A, CruzipainTrypanosoma cruziPotency39.81070.002014.677939.8107AID1476
LuciferasePhotinus pyralis (common eastern firefly)Potency0.95280.007215.758889.3584AID588342
thioredoxin reductaseRattus norvegicus (Norway rat)Potency32.64310.100020.879379.4328AID588453; AID588456
ATAD5 protein, partialHomo sapiens (human)Potency3.93370.004110.890331.5287AID493106; AID493107; AID504466; AID504467
Fumarate hydrataseHomo sapiens (human)Potency37.22120.00308.794948.0869AID1347053
TDP1 proteinHomo sapiens (human)Potency2.59290.000811.382244.6684AID686978
ThrombopoietinHomo sapiens (human)Potency0.31620.02517.304831.6228AID917; AID918
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency31.83260.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency15.84890.00137.762544.6684AID914; AID915
thyroid stimulating hormone receptorHomo sapiens (human)Potency12.58930.001318.074339.8107AID926; AID938
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency7.97520.001530.607315,848.9004AID1224819; AID1224820; AID1224821; AID1224823
polyproteinZika virusPotency37.22120.00308.794948.0869AID1347053
67.9K proteinVaccinia virusPotency10.00000.00018.4406100.0000AID720580
ParkinHomo sapiens (human)Potency0.81990.819914.830644.6684AID720573
P53Homo sapiens (human)Potency2.51190.07319.685831.6228AID504706
arylsulfatase AHomo sapiens (human)Potency0.02131.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.15190.035520.977089.1251AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency0.26120.016525.307841.3999AID602332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency19.95260.540617.639296.1227AID2364; AID2528
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency4.26640.01262.451825.0177AID485313
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency75.686323.934123.934123.9341AID1967
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency12.58930.316212.443531.6228AID902; AID924
atrial natriuretic peptide receptor 1 precursorHomo sapiens (human)Potency1.51010.134610.395030.1313AID1347049
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency0.46110.00419.984825.9290AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency17.78283.548119.542744.6684AID743266
DNA polymerase betaHomo sapiens (human)Potency44.66840.022421.010289.1251AID485314
atrial natriuretic peptide receptor 2 precursorHomo sapiens (human)Potency18.49270.00669.809418.4927AID1347050
ras-related protein Rab-9AHomo sapiens (human)Potency2.34380.00022.621531.4954AID485297
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency18.49270.00378.618923.2809AID2668
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency0.02240.050127.073689.1251AID588590
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency4.46680.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency4.46680.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency4.46680.15855.287912.5893AID540303
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency24.03530.00798.23321,122.0200AID2546; AID2551
survival motor neuron protein isoform dHomo sapiens (human)Potency7.94330.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency3.98110.031610.279239.8107AID884; AID885
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency17.78280.00106.000935.4813AID943
lamin isoform A-delta10Homo sapiens (human)Potency0.70790.891312.067628.1838AID1487
pyruvate kinase PKM isoform bHomo sapiens (human)Potency3.16232.511912.262825.1189AID954; AID958
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Integrin beta-3Homo sapiens (human)Potency12.58930.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency12.58930.316211.415731.6228AID924
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
TAR DNA-binding protein 43Homo sapiens (human)Potency3.54811.778316.208135.4813AID652104
GABA theta subunitRattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
Ataxin-2Homo sapiens (human)Potency0.63100.011912.222168.7989AID588378
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency3.98111.000012.224831.6228AID885
2,3-bisphosphoglycerate-independent phosphoglycerate mutaseLeishmania major strain FriedlinPotency23.93417.568615.230621.3313AID504548
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AcetylcholinesteraseElectrophorus electricus (electric eel)IC50 (µMol)100.00000.00000.94539.9400AID1555975; AID477064
cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)IC50 (µMol)1.23000.00001.18439.6140AID1659411
Cytochrome P450 1A1Homo sapiens (human)IC50 (µMol)0.26000.00791.24789.9000AID54201
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)0.02200.00011.774010.0000AID54216
Cytochrome P450 3A4Homo sapiens (human)Ki107.70000.00011.41629.9000AID589117
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)8.70000.00021.557410.0000AID403341; AID717354
Prostaglandin G/H synthase 2Homo sapiens (human)IC50 (µMol)0.29000.00010.995010.0000AID403340; AID717353
CholinesteraseEquus caballus (horse)IC50 (µMol)100.00000.00002.22149.4000AID1555976; AID477065
Cytochrome P450 1B1Homo sapiens (human)IC50 (µMol)0.05500.00130.86969.9000AID1453008; AID54231
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transient receptor potential cation channel subfamily V member 1Rattus norvegicus (Norway rat)EC50 (µMol)2.06000.00050.43182.3800AID1317246
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AlbuminHomo sapiens (human)Ka1.00001.00001.00001.0000AID1464926
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (262)

Processvia Protein(s)Taxonomy
positive regulation of cardiac muscle hypertrophycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of nitric oxide mediated signal transductioncGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
T cell proliferationcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of T cell proliferationcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP catabolic processcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
oocyte developmentcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of cardiac muscle contractioncGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
relaxation of cardiac musclecGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of oocyte developmentcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cAMP-mediated signalingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to starvationAlbuminHomo sapiens (human)
negative regulation of mitochondrial depolarizationAlbuminHomo sapiens (human)
cellular response to calcium ion starvationAlbuminHomo sapiens (human)
cellular oxidant detoxificationAlbuminHomo sapiens (human)
transportAlbuminHomo sapiens (human)
cellular response to organic cyclic compoundCytochrome P450 1A1Homo sapiens (human)
response to hypoxiaCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 1A1Homo sapiens (human)
lipid hydroxylationCytochrome P450 1A1Homo sapiens (human)
fatty acid metabolic processCytochrome P450 1A1Homo sapiens (human)
steroid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A1Homo sapiens (human)
steroid metabolic processCytochrome P450 1A1Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A1Homo sapiens (human)
amine metabolic processCytochrome P450 1A1Homo sapiens (human)
response to nematodeCytochrome P450 1A1Homo sapiens (human)
response to herbicideCytochrome P450 1A1Homo sapiens (human)
ethylene metabolic processCytochrome P450 1A1Homo sapiens (human)
coumarin metabolic processCytochrome P450 1A1Homo sapiens (human)
flavonoid metabolic processCytochrome P450 1A1Homo sapiens (human)
response to iron(III) ionCytochrome P450 1A1Homo sapiens (human)
insecticide metabolic processCytochrome P450 1A1Homo sapiens (human)
dibenzo-p-dioxin catabolic processCytochrome P450 1A1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A1Homo sapiens (human)
response to foodCytochrome P450 1A1Homo sapiens (human)
response to lipopolysaccharideCytochrome P450 1A1Homo sapiens (human)
response to vitamin ACytochrome P450 1A1Homo sapiens (human)
response to immobilization stressCytochrome P450 1A1Homo sapiens (human)
vitamin D metabolic processCytochrome P450 1A1Homo sapiens (human)
retinol metabolic processCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
9-cis-retinoic acid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
camera-type eye developmentCytochrome P450 1A1Homo sapiens (human)
nitric oxide metabolic processCytochrome P450 1A1Homo sapiens (human)
response to arsenic-containing substanceCytochrome P450 1A1Homo sapiens (human)
digestive tract developmentCytochrome P450 1A1Homo sapiens (human)
tissue remodelingCytochrome P450 1A1Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A1Homo sapiens (human)
response to hyperoxiaCytochrome P450 1A1Homo sapiens (human)
maternal process involved in parturitionCytochrome P450 1A1Homo sapiens (human)
hepatocyte differentiationCytochrome P450 1A1Homo sapiens (human)
cellular response to copper ionCytochrome P450 1A1Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A1Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleCytochrome P450 1A1Homo sapiens (human)
response to 3-methylcholanthreneCytochrome P450 1A1Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
cellular response to organic cyclic compoundCytochrome P450 1B1Homo sapiens (human)
angiogenesisCytochrome P450 1B1Homo sapiens (human)
trabecular meshwork developmentCytochrome P450 1B1Homo sapiens (human)
DNA modificationCytochrome P450 1B1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1B1Homo sapiens (human)
nitric oxide biosynthetic processCytochrome P450 1B1Homo sapiens (human)
cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to nutrientCytochrome P450 1B1Homo sapiens (human)
steroid metabolic processCytochrome P450 1B1Homo sapiens (human)
estrogen metabolic processCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell population proliferationCytochrome P450 1B1Homo sapiens (human)
male gonad developmentCytochrome P450 1B1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressCytochrome P450 1B1Homo sapiens (human)
toxin metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionCytochrome P450 1B1Homo sapiens (human)
positive regulation of smooth muscle cell migrationCytochrome P450 1B1Homo sapiens (human)
sterol metabolic processCytochrome P450 1B1Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 1B1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
collagen fibril organizationCytochrome P450 1B1Homo sapiens (human)
adrenal gland developmentCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell migrationCytochrome P450 1B1Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityCytochrome P450 1B1Homo sapiens (human)
response to follicle-stimulating hormoneCytochrome P450 1B1Homo sapiens (human)
response to estradiolCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell adhesion mediated by integrinCytochrome P450 1B1Homo sapiens (human)
benzene-containing compound metabolic processCytochrome P450 1B1Homo sapiens (human)
retinol metabolic processCytochrome P450 1B1Homo sapiens (human)
retinal metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of apoptotic processCytochrome P450 1B1Homo sapiens (human)
blood vessel endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
estrous cycleCytochrome P450 1B1Homo sapiens (human)
positive regulation of translationCytochrome P450 1B1Homo sapiens (human)
positive regulation of angiogenesisCytochrome P450 1B1Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATCytochrome P450 1B1Homo sapiens (human)
membrane lipid catabolic processCytochrome P450 1B1Homo sapiens (human)
response to arsenic-containing substanceCytochrome P450 1B1Homo sapiens (human)
blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
retinal blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
ganglion developmentCytochrome P450 1B1Homo sapiens (human)
cellular response to hydrogen peroxideCytochrome P450 1B1Homo sapiens (human)
cellular response to cAMPCytochrome P450 1B1Homo sapiens (human)
cellular response to tumor necrosis factorCytochrome P450 1B1Homo sapiens (human)
cellular response to luteinizing hormone stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to cortisol stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to progesterone stimulusCytochrome P450 1B1Homo sapiens (human)
response to dexamethasoneCytochrome P450 1B1Homo sapiens (human)
endothelial cell-cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to indole-3-methanolCytochrome P450 1B1Homo sapiens (human)
cellular response to toxic substanceCytochrome P450 1B1Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
response to 3-methylcholanthreneCytochrome P450 1B1Homo sapiens (human)
regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of DNA biosynthetic processCytochrome P450 1B1Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (80)

Processvia Protein(s)Taxonomy
3',5'-cyclic-nucleotide phosphodiesterase activitycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
protein bindingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP bindingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
metal ion bindingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
oxygen bindingAlbuminHomo sapiens (human)
DNA bindingAlbuminHomo sapiens (human)
fatty acid bindingAlbuminHomo sapiens (human)
copper ion bindingAlbuminHomo sapiens (human)
protein bindingAlbuminHomo sapiens (human)
toxic substance bindingAlbuminHomo sapiens (human)
antioxidant activityAlbuminHomo sapiens (human)
pyridoxal phosphate bindingAlbuminHomo sapiens (human)
identical protein bindingAlbuminHomo sapiens (human)
protein-folding chaperone bindingAlbuminHomo sapiens (human)
exogenous protein bindingAlbuminHomo sapiens (human)
enterobactin bindingAlbuminHomo sapiens (human)
monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
iron ion bindingCytochrome P450 1A1Homo sapiens (human)
protein bindingCytochrome P450 1A1Homo sapiens (human)
arachidonic acid monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A1Homo sapiens (human)
oxidoreductase activity, acting on diphenols and related substances as donorsCytochrome P450 1A1Homo sapiens (human)
flavonoid 3'-monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
oxygen bindingCytochrome P450 1A1Homo sapiens (human)
enzyme bindingCytochrome P450 1A1Homo sapiens (human)
heme bindingCytochrome P450 1A1Homo sapiens (human)
Hsp70 protein bindingCytochrome P450 1A1Homo sapiens (human)
demethylase activityCytochrome P450 1A1Homo sapiens (human)
Hsp90 protein bindingCytochrome P450 1A1Homo sapiens (human)
aromatase activityCytochrome P450 1A1Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid omega-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
monooxygenase activityCytochrome P450 1B1Homo sapiens (human)
iron ion bindingCytochrome P450 1B1Homo sapiens (human)
protein bindingCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
heme bindingCytochrome P450 1B1Homo sapiens (human)
aromatase activityCytochrome P450 1B1Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1B1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (58)

Processvia Protein(s)Taxonomy
cellular_componentcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytosolcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
extracellular regionAlbuminHomo sapiens (human)
extracellular spaceAlbuminHomo sapiens (human)
nucleusAlbuminHomo sapiens (human)
endoplasmic reticulumAlbuminHomo sapiens (human)
endoplasmic reticulum lumenAlbuminHomo sapiens (human)
Golgi apparatusAlbuminHomo sapiens (human)
platelet alpha granule lumenAlbuminHomo sapiens (human)
extracellular exosomeAlbuminHomo sapiens (human)
blood microparticleAlbuminHomo sapiens (human)
protein-containing complexAlbuminHomo sapiens (human)
cytoplasmAlbuminHomo sapiens (human)
mitochondrial inner membraneCytochrome P450 1A1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A1Homo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionCytochrome P450 1B1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1B1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1B1Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (208)

Assay IDTitleYearJournalArticle
AID1883412Induction of apoptosis in human LS174T cells assessed as upregulation of cleaved PARP expression measured after 48 hrs by Western blot analysis
AID1883386Induction of cell cycle arrest in human LS174T cells assessed as downregulation of cyclin E expression measured after 24 hrs by Western blot analysis
AID1883407Induction of apoptosis in human LS174T cells assessed as total cell death at 20 uM measured after 48 hrs by AnnexinV-FITC/PI staining based flowcytometry analysis relative to control
AID1883399Induction of cell cycle arrest in human LS174T cells assessed as accumulation of cells at sub-G1 phase at 20 uM measured at 36 hrs by RNase A/propidium iodide staining based flow cytometric analysis (Rvb = 0.7 %)
AID1883392Induction of cell cycle arrest in human LS174T cells assessed as accumulation of cells at G0/G1 phase at 20 uM measured at 12 hrs by RNase A/propidium iodide staining based flow cytometric analysis (Rvb = 74.8 %)
AID1883406Induction of cell cycle arrest in human LS174T cells assessed as accumulation of cells at G2/M phase at 20 uM measured at 48 hrs by RNase A/propidium iodide staining based flow cytometric analysis (Rvb = 12.9 %)
AID1464923Solubility of the compound in minimal essential medium at 1 to 2 mg after 24 hrs in absence of 10% FCS by HPLC-UV based shake-flask method2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Cytotoxic properties of the alkaloid rutaecarpine and its oligocyclic derivatives and chemical modifications to enhance water-solubility.
AID395321Vasodilative activity against KCl-precontracted Sprague-Dawley rat thoracic aorta assessed as reduction in phenylepinephrine-induced contraction2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Synthesis and vasodilator effects of rutaecarpine analogues which might be involved transient receptor potential vanilloid subfamily, member 1 (TRPV1).
AID1883397Induction of cell cycle arrest in human LS174T cells assessed as accumulation of cells at S phase at 20 uM measured at 24 hrs by RNase A/propidium iodide staining based flow cytometric analysis (Rvb = 11.4 %)
AID1883365Antiproliferative activity against human HCT-116 cells harboring beta-catenin mutant assessed as reduction in cell viability measured after 72 hrs by SRB assay
AID1883420Antitumor activity against human LS174T cells xenografted in BALB/c nude mouse assessed as reduction in tumor weight at 10 mg/kg, ip administered 3 times per week for 21 days by electronic caliper method
AID1317292Partial antagonist activity at rat TRPV1 expressed in HEK293 cells assessed as inhibition of proton-induced channel current at 2 uM at -60 mV holding potential co-treated with proton by whole-cell patch clamp method2016Journal of natural products, 05-27, Volume: 79, Issue:5
Partial Activation and Inhibition of TRPV1 Channels by Evodiamine and Rutaecarpine, Two Major Components of the Fruits of Evodia rutaecarpa.
AID1883419Antitumor activity against human LS174T cells xenografted in BALB/c nude mouse assessed as reduction in tumor volume at 30 mg/kg, ip administered 3 times per week for 21 days by electronic caliper method
AID1317237Agonist activity at human TRPA1 channel expressed in HEK293 cells assessed as induction of channel current at 50 uM and -60 mV holding potential by voltage-clamp method2016Journal of natural products, 05-27, Volume: 79, Issue:5
Partial Activation and Inhibition of TRPV1 Channels by Evodiamine and Rutaecarpine, Two Major Components of the Fruits of Evodia rutaecarpa.
AID1883410Induction of apoptosis in human LS174T cells assessed as upregulation of cleaved caspase-9 expression measured after 48 hrs by Western blot analysis
AID1883379Induction of cell cycle arrest in human LS174T cells assessed as accumulation of cells at G0/G1 phase at 10 uM measured after 24 hrs by RNase A/propidium iodide staining based flow cytometric analysis (Rvb = 71.7 %)
AID1883432Downregulation of cyclin D1 expression in tumor of BALB/c mouse xenografted with human LS174T cells at 10 to 30 mg/kg, ip administered 3 times per week for 21 days by immunohistochemical based analysis
AID1883370Downregulation of beta-catenin expression in human LS174T cells at 2.5 to 20 uM incubated for 24 hrs by Western blot analysis
AID1883366Antiproliferative activity against human LS174T cells harboring beta-catenin mutant assessed as reduction in cell viability measured after 72 hrs by SRB assay
AID354594Vasodilatory activity in Sprague-Dawley rat endothelium-intact thoracic aortic ring assessed as inhibition of phenylephrine-induced contraction at 100 uM1996Journal of natural products, Apr, Volume: 59, Issue:4
Comparative study of the vasodilatory effects of three quinazoline alkaloids isolated from Evodia rutaecarpa.
AID1543748Vasodilating activity in Sprague-Dawley rat aortic rings assessed as reduction in phenylephrine-induced contractions at 1:1 ratio of test compound to furoxan2019European journal of medicinal chemistry, Apr-15, Volume: 168Dual-targeting Rutaecarpine-NO donor hybrids as novel anti-hypertensive agents by promoting release of CGRP.
AID1883403Induction of cell cycle arrest in human LS174T cells assessed as accumulation of cells at sub-G1 phase at 20 uM measured at 48 hrs by RNase A/propidium iodide staining based flow cytometric analysis (Rvb = 0.7 %)
AID1464918Aqueous solubility of the compound in phosphate buffered saline at pH 6.8 after 24 hrs by HPLC-UV based shake-flask method2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Cytotoxic properties of the alkaloid rutaecarpine and its oligocyclic derivatives and chemical modifications to enhance water-solubility.
AID1883416Downregulation of snail expression in human LS174T cells at up to 8 uM incubated for 24 hrs by Western blot analysis
AID1883395Induction of cell cycle arrest in human LS174T cells assessed as accumulation of cells at sub-G1 phase at 20 uM measured at 24 hrs by RNase A/propidium iodide staining based flow cytometric analysis (Rvb = 0.7 %)
AID1543751Vasodilating activity in Sprague-Dawley rat aortic rings assessed as reduction in phenylephrine-induced contractions at 1:1 ratio of test compound to furoxan relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Dual-targeting Rutaecarpine-NO donor hybrids as novel anti-hypertensive agents by promoting release of CGRP.
AID1317246Agonist activity at rat TRPV1 channel expressed in HEK293 cells assessed as induction of channel current at -60 mV holding potential by whole-cell patch-clamp method2016Journal of natural products, 05-27, Volume: 79, Issue:5
Partial Activation and Inhibition of TRPV1 Channels by Evodiamine and Rutaecarpine, Two Major Components of the Fruits of Evodia rutaecarpa.
AID477064inhibition of electric eel AChE by Ellman's method2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors.
AID661112Agonist activity at ECMV genomic RNA internal ribosomal entry site in human HuH7 cells after 24 hrs by firefly luciferase reporter gene assay2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Latent hit series hidden in high-throughput screening data.
AID403341Inhibition of COX12005Journal of natural products, Jul, Volume: 68, Issue:7
Expanding the ChemGPS chemical space with natural products.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1464924Solubility of the compound in minimal essential medium at 1 to 2 mg after 24 hrs in presence of 10% FCS by HPLC-UV based shake-flask method2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Cytotoxic properties of the alkaloid rutaecarpine and its oligocyclic derivatives and chemical modifications to enhance water-solubility.
AID354607Binding affinity to DHP binding site of L-type calcium channel by radioligand binding assay1996Journal of natural products, Apr, Volume: 59, Issue:4
Comparative study of the vasodilatory effects of three quinazoline alkaloids isolated from Evodia rutaecarpa.
AID1883408Induction of apoptosis in human LS174T cells assessed as total cell death at 30 uM measured after 48 hrs by AnnexinV-FITC/PI staining based flowcytometry analysis relative to control
AID717353Inhibition of COX2 in BMMC cells assessed as PGD2 generation2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Analogue-based design, synthesis and docking of non-steroidal anti-inflammatory agents. Part 2: methyl sulfanyl/methyl sulfonyl substituted 2,3-diaryl-2,3-dihydro-1H-quinazolin-4-ones.
AID1317238Agonist activity at rat TRPV1 channel expressed in HEK293 cells assessed as induction of inward current at 50 uM and -60 mV holding potential by whole-cell patch-clamp method2016Journal of natural products, 05-27, Volume: 79, Issue:5
Partial Activation and Inhibition of TRPV1 Channels by Evodiamine and Rutaecarpine, Two Major Components of the Fruits of Evodia rutaecarpa.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1317235Induction of channel current in human HEK293 cells at 50 uM at -60 mV holding potential by voltage-clamp method2016Journal of natural products, 05-27, Volume: 79, Issue:5
Partial Activation and Inhibition of TRPV1 Channels by Evodiamine and Rutaecarpine, Two Major Components of the Fruits of Evodia rutaecarpa.
AID1883363Antiproliferative activity against human SW480 cells harboring wild type beta-catenin assessed as reduction in cell viability measured after 72 hrs by SRB assay
AID1883364Antiproliferative activity against human HCT-15 cells harboring wild type beta-catenin assessed as reduction in cell viability measured after 72 hrs by SRB assay
AID54203Ratio for inhibition of Cytochrome P450 1A1 to that of Cytochrome P450 1A22003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
Effect of structural modification on the inhibitory selectivity of rutaecarpine derivatives on human CYP1A1, CYP1A2, and CYP1B1.
AID1883362Antiproliferative activity against human RKO cells harboring wild type beta-catenin assessed as reduction in cell viability measured after 72 hrs by SRB assay
AID1883411Induction of apoptosis in human LS174T cells assessed as upregulation of cleaved caspase-3 expression measured after 48 hrs by Western blot analysis
AID1453008Inhibition of human CYP1B1 expressed in Escherichia coli2017European journal of medicinal chemistry, Jul-28, Volume: 135Inhibitors of cytochrome P450 (CYP) 1B1.
AID1883435Induction of apoptosis in human LS174T cells assessed as increase in late apoptotic cells at 20 to 40 uM measured after 48 hrs by AnnexinV-FITC/PI staining based flowcytometry analysis
AID1317275Partial antagonist activity at rat TRPV1 expressed in HEK293 cells assessed as effect on capsaicin-induced inward current at 10 uM by whole-cell patch clamp method2016Journal of natural products, 05-27, Volume: 79, Issue:5
Partial Activation and Inhibition of TRPV1 Channels by Evodiamine and Rutaecarpine, Two Major Components of the Fruits of Evodia rutaecarpa.
AID1883417Downregulation of N-cadherin expression in human LS174T cells at up to 8 uM incubated for 24 hrs by Western blot analysis
AID477065inhibition of equine serum BuChE by Ellman's method2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors.
AID1883372Downregulation of survivin expression in human LS174T cells at 2.5 to 20 uM incubated for 24 hrs by Western blot analysis
AID589117Mechanism based inhibition of human cytochrome P450 3A4 measured by (14C)formaldehyde production from (N-methyl-14C)-erythromycin2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID1464917Aqueous solubility of the compound in deionized water after 24 hrs by HPLC-UV based shake-flask method2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Cytotoxic properties of the alkaloid rutaecarpine and its oligocyclic derivatives and chemical modifications to enhance water-solubility.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1883421Antitumor activity against human LS174T cells xenografted in BALB/c nude mouse assessed as reduction in tumor weight at 30 mg/kg, ip administered 3 times per week for 21 days by electronic caliper method
AID1317245Agonist activity at rat TRPV1 channel expressed in HEK293 cells assessed as induction of channel current at -60 mV holding potential in presence of capsazepine by whole-cell patch-clamp method2016Journal of natural products, 05-27, Volume: 79, Issue:5
Partial Activation and Inhibition of TRPV1 Channels by Evodiamine and Rutaecarpine, Two Major Components of the Fruits of Evodia rutaecarpa.
AID1883429Downregulation of N-cadherin expression in tumor of BALB/c mouse xenografted with human LS174T cells at 10 to 30 mg/kg, ip administered 3 times per week for 21 days by Western blot analysis
AID1555978Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM incubated for 2 hrs under dark condition relative to control2019European journal of medicinal chemistry, Sep-01, Volume: 177Design, synthesis, and biological evaluation of rutacecarpine derivatives as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID54201Inhibition of Cytochrome P450 1A1 enzyme in bacterial membrane expressing human P450s2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
Effect of structural modification on the inhibitory selectivity of rutaecarpine derivatives on human CYP1A1, CYP1A2, and CYP1B1.
AID1883378Induction of cell cycle arrest in human LS174T cells assessed as accumulation of cells at sub-G1 phase at 10 uM measured after 24 hrs by RNase A/propidium iodide staining based flow cytometric analysis (Rvb = 1.3 %)
AID1883425Downregulation of survivin expression in tumor of BALB/c mouse xenografted with human LS174T cells at 10 to 30 mg/kg, ip administered 3 times per week for 21 days by Western blot analysis
AID1883424Downregulation of c-myc protein expression in tumor of BALB/c mouse xenografted with human LS174T cells at 10 to 30 mg/kg, ip administered 3 times per week for 21 days by Western blot analysis
AID1883389Induction of cell cycle arrest in human LS174T cells assessed as downregulation of CDK4 expression measured after 24 hrs by Western blot analysis
AID1543757Increase in CGRP level in Sprague-Dawley rat blood at 20 to 40 mg/kg, ip by ELISA2019European journal of medicinal chemistry, Apr-15, Volume: 168Dual-targeting Rutaecarpine-NO donor hybrids as novel anti-hypertensive agents by promoting release of CGRP.
AID1883430Downregulation of Ki-67 expression in tumor of BALB/c mouse xenografted with human LS174T cells at 10 to 30 mg/kg, ip administered 3 times per week for 21 days by immunohistochemical based analysis
AID1883415Inhibition of cell invasion in human LS174T cells incubated for 24 hrs by transwell assay
AID1317289Partial antagonist activity at rat TRPV1 expressed in HEK293 cells assessed as inhibition of capsaicin-induced inward current at 50 uM and -60 mV holding potential pretreated for 60 secs prior to capsaicin-challenge by whole-cell patch-clamp method2016Journal of natural products, 05-27, Volume: 79, Issue:5
Partial Activation and Inhibition of TRPV1 Channels by Evodiamine and Rutaecarpine, Two Major Components of the Fruits of Evodia rutaecarpa.
AID717354Inhibition of COX1 in BMMC cells assessed as PGD2 generation2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Analogue-based design, synthesis and docking of non-steroidal anti-inflammatory agents. Part 2: methyl sulfanyl/methyl sulfonyl substituted 2,3-diaryl-2,3-dihydro-1H-quinazolin-4-ones.
AID1883401Induction of cell cycle arrest in human LS174T cells assessed as accumulation of cells at S phase at 20 uM measured at 36 hrs by RNase A/propidium iodide staining based flow cytometric analysis (Rvb = 11.4 %)
AID54231Inhibition of Cytochrome P450 1B1 enzyme in bacterial membrane expressing human P450s2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
Effect of structural modification on the inhibitory selectivity of rutaecarpine derivatives on human CYP1A1, CYP1A2, and CYP1B1.
AID1883376Induction of cell cycle arrest in human LS174T cells assessed as accumulation of cells at S phase at 5 uM measured after 24 hrs by RNase A/propidium iodide staining based flow cytometric analysis (Rvb = 14.5 %)
AID1883433Downregulation of N-cadherin expression in tumor of BALB/c mouse xenografted with human LS174T cells at 10 to 30 mg/kg, ip administered 3 times per week for 21 days by immunohistochemical based analysis
AID1317243Agonist activity at rat TRPV1 channel expressed in HEK293 cells assessed as reversal potential at 50 uM and -60 mV holding potential by whole-cell patch-clamp method2016Journal of natural products, 05-27, Volume: 79, Issue:5
Partial Activation and Inhibition of TRPV1 Channels by Evodiamine and Rutaecarpine, Two Major Components of the Fruits of Evodia rutaecarpa.
AID1883361Inhibition of Wnt/beta-catenin transactivation signalling in HEK293 cells transfected with renilla luciferase and TOPFlash reporter gene incubated for 24 hrs by dual-luciferase assay
AID1883382Induction of cell cycle arrest in human LS174T cells assessed as accumulation of cells at G1 phase at 20 uM measured after 24 hrs by RNase A/propidium iodide staining based flow cytometric analysis (Rvb = 1.3 %)
AID1883413Induction of apoptosis in human LS174T cells assessed as downregulation of survivin expression measured after 48 hrs by Western blot analysis
AID1883368Antiproliferative activity against human CCD-18Co cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
AID54216Inhibition of Cytochrome P450 1A2 enzyme in bacterial membrane expressing human P450s2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
Effect of structural modification on the inhibitory selectivity of rutaecarpine derivatives on human CYP1A1, CYP1A2, and CYP1B1.
AID1883393Induction of cell cycle arrest in human LS174T cells assessed as accumulation of cells at S phase at 20 uM measured at 12 hrs by RNase A/propidium iodide staining based flow cytometric analysis (Rvb = 11.4 %)
AID1883414Inhibition of cell migration in human LS174T cells assessed as reduction in wound closure incubated for 24 hrs by wound healing assay
AID1883369Inhibition of Wnt/beta-catenin transactivation signalling in human LS174T cells transfected with renilla luciferase and TOPFlash reporter gene incubated for 24 hrs by dual-luciferase assay
AID1543750Vasodilating activity in Sprague-Dawley rat aortic rings assessed as reduction in phenylephrine-induced contractions relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Dual-targeting Rutaecarpine-NO donor hybrids as novel anti-hypertensive agents by promoting release of CGRP.
AID1883426Downregulation of cyclin-D1 expression in tumor of BALB/c mouse xenografted with human LS174T cells at 10 to 30 mg/kg, ip administered 3 times per week for 21 days by Western blot analysis
AID1883390Induction of cell cycle arrest in human LS174T cells assessed as downregulation of CDK6 expression measured after 24 hrs by Western blot analysis
AID1883383Induction of cell cycle arrest in human LS174T cells assessed as accumulation of cells at G0/G1 phase at 20 uM measured after 24 hrs by RNase A/propidium iodide staining based flow cytometric analysis (Rvb = 71.7 %)
AID1883409Induction of apoptosis in human LS174T cells assessed as total cell death at 40 uM measured after 48 hrs by AnnexinV-FITC/PI staining based flowcytometry analysis relative to control
AID1555977Selectivity index, ratio of IC50 for electric eel AChE to IC50 for equine serum BuChE2019European journal of medicinal chemistry, Sep-01, Volume: 177Design, synthesis, and biological evaluation of rutacecarpine derivatives as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID1555976Inhibition of equine serum BuChE using S-butyrylthiocholine iodide as substrate preincubated with enzyme for 30 mins followed by substrate addition and measured after 30 mins by Ellman's method2019European journal of medicinal chemistry, Sep-01, Volume: 177Design, synthesis, and biological evaluation of rutacecarpine derivatives as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID1883373Downregulation of cyclin D1 expression in human LS174T cells at 2.5 to 20 uM incubated for 24 hrs by Western blot analysis
AID1883381Induction of cell cycle arrest in human LS174T cells assessed as accumulation of cells at G2/M phase at 10 uM measured after 24 hrs by RNase A/propidium iodide staining based flow cytometric analysis (Rvb = 12.2 %)
AID354597Vasodilatory activity in Sprague-Dawley rat endothelium-denuded thoracic aortic ring assessed as inhibition of phenylephrine-induced contraction1996Journal of natural products, Apr, Volume: 59, Issue:4
Comparative study of the vasodilatory effects of three quinazoline alkaloids isolated from Evodia rutaecarpa.
AID1883367Antiproliferative activity against human CCD-841CoN cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
AID354595Vasodilatory activity in Sprague-Dawley rat endothelium-intact thoracic aortic ring assessed as inhibition of phenylephrine-induced contraction1996Journal of natural products, Apr, Volume: 59, Issue:4
Comparative study of the vasodilatory effects of three quinazoline alkaloids isolated from Evodia rutaecarpa.
AID354596Vasodilatory activity in Sprague-Dawley rat endothelium-intact thoracic aortic ring assessed as inhibition of phenylephrine-induced contraction at 0.1 to 100 uM1996Journal of natural products, Apr, Volume: 59, Issue:4
Comparative study of the vasodilatory effects of three quinazoline alkaloids isolated from Evodia rutaecarpa.
AID1883427Downregulation of MMP-7 expression in tumor of BALB/c mouse xenografted with human LS174T cells at 10 to 30 mg/kg, ip administered 3 times per week for 21 days by Western blot analysis
AID354601Vasodilatory activity in endothelium-denuded Sprague-Dawley rat thoracic aortic ring assessed as inhibition of phenylephrine-induced contraction preincubated with TEA for 1 hr1996Journal of natural products, Apr, Volume: 59, Issue:4
Comparative study of the vasodilatory effects of three quinazoline alkaloids isolated from Evodia rutaecarpa.
AID1883402Induction of cell cycle arrest in human LS174T cells assessed as accumulation of cells at G2/M phase at 20 uM measured at 36 hrs by RNase A/propidium iodide staining based flow cytometric analysis (Rvb = 12.9 %)
AID1883422Toxicity in BALB/c nude mouse xenografted with human LS174T cells assessed as effect on body weight at 10 to 30 mg/kg, ip administered 3 times per week for 21 days
AID1464927Binding affinity to human Alpha 1-acid glycoprotein2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Cytotoxic properties of the alkaloid rutaecarpine and its oligocyclic derivatives and chemical modifications to enhance water-solubility.
AID1883359Induction of cell cycle arrest in human LS174T cells assessed as accumulation of cells at sub-G1 phase at 20 uM measured at 12 hrs by RNase A/propidium iodide staining based flow cytometric analysis (Rvb = 0.7 %)
AID277075Inhibition of human MMP9 by quenched fluorescense assay2006Bioorganic & medicinal chemistry letters, Dec-15, Volume: 16, Issue:24
Natural inhibitors targeting osteoclast-mediated bone resorption.
AID1883404Induction of cell cycle arrest in human LS174T cells assessed as accumulation of cells at G0/G1 phase at 20 uM measured at 48 hrs by RNase A/propidium iodide staining based flow cytometric analysis (Rvb = 74.8 %)
AID1883418Downregulation of MMP-7 expression in human LS174T cells at up to 8 uM incubated for 24 hrs by Western blot analysis
AID1883384Induction of cell cycle arrest in human LS174T cells assessed as accumulation of cells at S phase at 20 uM measured after 24 hrs by RNase A/propidium iodide staining based flow cytometric analysis (Rvb = 14.5 %)
AID1883434Induction of apoptosis in human LS174T cells assessed as increase in early apoptotic cells at 20 to 40 uM measured after 48 hrs by AnnexinV-FITC/PI staining based flowcytometry analysis
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1883371Downregulation of c-Myc expression in human LS174T cells at 2.5 to 20 uM incubated for 24 hrs by Western blot analysis
AID661114Cytotoxicity against human HuH7 cells after 24 hrs by resazurin reduction assay2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Latent hit series hidden in high-throughput screening data.
AID1464921Cytotoxicity against human HeLa cells by MTT assay2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Cytotoxic properties of the alkaloid rutaecarpine and its oligocyclic derivatives and chemical modifications to enhance water-solubility.
AID1883398Induction of cell cycle arrest in human LS174T cells assessed as accumulation of cells at G2/M phase at 20 uM measured at 24 hrs by RNase A/propidium iodide staining based flow cytometric analysis (Rvb = 12.9 %)
AID1464925Solubility of the compound in water2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Cytotoxic properties of the alkaloid rutaecarpine and its oligocyclic derivatives and chemical modifications to enhance water-solubility.
AID1883375Induction of cell cycle arrest in human LS174T cells assessed as accumulation of cells at G0/G1 phase at 5 uM measured after 24 hrs by RNase A/propidium iodide staining based flow cytometric analysis (Rvb = 71.7 %)
AID1317241Agonist activity at rat TRPV1 channel expressed in HEK293 cells assessed as outward rectifying current at 50 uM and -60 mV holding potential by whole-cell patch-clamp method2016Journal of natural products, 05-27, Volume: 79, Issue:5
Partial Activation and Inhibition of TRPV1 Channels by Evodiamine and Rutaecarpine, Two Major Components of the Fruits of Evodia rutaecarpa.
AID1883431Downregulation of c-Myc expression in tumor of BALB/c mouse xenografted with human LS174T cells at 10 to 30 mg/kg, ip administered 3 times per week for 21 days by immunohistochemical based analysis
AID1883380Induction of cell cycle arrest in human LS174T cells assessed as accumulation of cells at S phase at 10 uM measured after 24 hrs by RNase A/propidium iodide staining based flow cytometric analysis (Rvb = 14.5 %)
AID54372Ratio for inhibition of Cytochrome P450 1B1 to that of Cytochrome P450 1A22003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
Effect of structural modification on the inhibitory selectivity of rutaecarpine derivatives on human CYP1A1, CYP1A2, and CYP1B1.
AID1317293Agonist activity at rat TRPV1 channel expressed in HEK293 cells assessed as induction of maximum channel current at 50 uM at -60 mV holding potential by whole-cell patch-clamp method2016Journal of natural products, 05-27, Volume: 79, Issue:5
Partial Activation and Inhibition of TRPV1 Channels by Evodiamine and Rutaecarpine, Two Major Components of the Fruits of Evodia rutaecarpa.
AID1659411Inhibition of PDE5A (unknown origin)2020Bioorganic & medicinal chemistry letters, 05-01, Volume: 30, Issue:9
Novel PDE5 inhibitors derived from rutaecarpine for the treatment of Alzheimer's disease.
AID1883396Induction of cell cycle arrest in human LS174T cells assessed as accumulation of cells at G0/G1 phase at 20 uM measured at 24 hrs by RNase A/propidium iodide staining based flow cytometric analysis (Rvb = 74.8 %)
AID1317297Desensitization of rat TRPV1 expressed in HEK293 cells at 50 uM for 20 sec at -60 mV holding potential in absence of extracellular calcium by whole-cell patch clamp method2016Journal of natural products, 05-27, Volume: 79, Issue:5
Partial Activation and Inhibition of TRPV1 Channels by Evodiamine and Rutaecarpine, Two Major Components of the Fruits of Evodia rutaecarpa.
AID1555975Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 30 mins followed by substrate addition and measured after 30 mins by Ellman's method2019European journal of medicinal chemistry, Sep-01, Volume: 177Design, synthesis, and biological evaluation of rutacecarpine derivatives as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID1883428Downregulation of snail protein expression in tumor of BALB/c mouse xenografted with human LS174T cells at 10 to 30 mg/kg, ip administered 3 times per week for 21 days by Western blot analysis
AID1883391Induction of cell cycle arrest in human LS174T cells assessed as upregulation of p21 expression measured after 24 hrs by Western blot analysis
AID1464919Aqueous solubility of the compound in phosphate buffered saline at pH 7.4 after 24 hrs by HPLC-UV based shake-flask method2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Cytotoxic properties of the alkaloid rutaecarpine and its oligocyclic derivatives and chemical modifications to enhance water-solubility.
AID1464926Binding affinity to human serum albumin by affinity chromatographic method2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Cytotoxic properties of the alkaloid rutaecarpine and its oligocyclic derivatives and chemical modifications to enhance water-solubility.
AID1883374Induction of cell cycle arrest in human LS174T cells assessed as accumulation of cells at sub-G1 phase at 5 uM measured after 24 hrs by RNase A/propidium iodide staining based flow cytometric analysis (Rvb = 1.3 %)
AID354598Vasodilatory activity in Sprague-Dawley rat endothelium-denuded thoracic aortic ring assessed as inhibition of phenylephrine-induced contraction at 0.1 to 100 uM1996Journal of natural products, Apr, Volume: 59, Issue:4
Comparative study of the vasodilatory effects of three quinazoline alkaloids isolated from Evodia rutaecarpa.
AID1317290Partial antagonist activity at rat TRPV1 expressed in HEK293 cells assessed as inhibition of proton-induced channel current at 1 or 50 uM and -60 mV holding potential pretreated for 60 secs prior to proton-challenge by whole-cell patch clamp method (Rvb =2016Journal of natural products, 05-27, Volume: 79, Issue:5
Partial Activation and Inhibition of TRPV1 Channels by Evodiamine and Rutaecarpine, Two Major Components of the Fruits of Evodia rutaecarpa.
AID1883360Antitumor activity against human LS174T cells xenografted in BALB/c nude mouse assessed as reduction in tumor volume at 10 mg/kg, ip administered 3 times per week for 21 days by electronic caliper method
AID1883400Induction of cell cycle arrest in human LS174T cells assessed as accumulation of cells at G0/G1 phase at 20 uM measured at 36 hrs by RNase A/propidium iodide staining based flow cytometric analysis (Rvb = 74.8 %)
AID1883387Induction of cell cycle arrest in human LS174T cells assessed as downregulation of cyclin D1 expression measured after 24 hrs by Western blot analysis
AID661115Agonist activity at ECMV genomic RNA internal ribosomal entry site in human HuH7 cells assessed as activity measured at the highest concentration after 24 hrs by firefly luciferase reporter gene assay relative to control2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Latent hit series hidden in high-throughput screening data.
AID1883385Induction of cell cycle arrest in human LS174T cells assessed as accumulation of cells at G2/M phase at 20 uM measured after 24 hrs by RNase A/propidium iodide staining based flow cytometric analysis (Rvb = 12.2 %)
AID1543749Vasodilating activity in Sprague-Dawley rat aortic rings assessed as reduction in phenylephrine-induced contractions2019European journal of medicinal chemistry, Apr-15, Volume: 168Dual-targeting Rutaecarpine-NO donor hybrids as novel anti-hypertensive agents by promoting release of CGRP.
AID1317251Desensitization of rat TRPV1 expressed in HEK293 cells at 50 uM for 30 sec at -60 mV holding potential in presence of extracellular calcium by whole-cell patch clamp method2016Journal of natural products, 05-27, Volume: 79, Issue:5
Partial Activation and Inhibition of TRPV1 Channels by Evodiamine and Rutaecarpine, Two Major Components of the Fruits of Evodia rutaecarpa.
AID1883388Induction of cell cycle arrest in human LS174T cells assessed as downregulation of CDK2 expression measured after 24 hrs by Western blot analysis
AID1883377Induction of cell cycle arrest in human LS174T cells assessed as accumulation of cells at G2/M phase at 5 uM measured after 24 hrs by RNase A/propidium iodide staining based flow cytometric analysis (Rvb = 12.2 %)
AID403340Inhibition of COX22005Journal of natural products, Jul, Volume: 68, Issue:7
Expanding the ChemGPS chemical space with natural products.
AID1883405Induction of cell cycle arrest in human LS174T cells assessed as accumulation of cells at S phase at 20 uM measured at 48 hrs by RNase A/propidium iodide staining based flow cytometric analysis (Rvb = 11.4 %)
AID1883423Toxicity in BALB/c nude mouse xenografted with human LS174T cells assessed as effect on body weight at 30 mg/kg, IP administered 3 times per week for 21 days
AID1555985Inhibition of self-mediated amyloid beta (1 to 42) (unknown origin) aggregation at 100 uM incubated for 48 hrs by thioflavin-T fluorescence assay relative to control2019European journal of medicinal chemistry, Sep-01, Volume: 177Design, synthesis, and biological evaluation of rutacecarpine derivatives as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID1883394Induction of cell cycle arrest in human LS174T cells assessed as accumulation of cells at G2/M phase at 20 uM measured at 12 hrs by RNase A/propidium iodide staining based flow cytometric analysis (Rvb = 12.9 %)
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347158ZIKV-mCherry secondary qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347164384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (231)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (0.87)18.7374
1990's12 (5.19)18.2507
2000's76 (32.90)29.6817
2010's99 (42.86)24.3611
2020's42 (18.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.66 (24.57)
Research Supply Index5.47 (2.92)
Research Growth Index5.62 (4.65)
Search Engine Demand Index61.55 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (30.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.43%)5.53%
Reviews9 (3.83%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other225 (95.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]